BioSpace News Archive

Sun Life and Maxwell Health have launched a combined benefits technology solution, providing employers and their employees with an intuitive digital benefits experience.

Apexigen, Inc., a clinical-stage biopharmaceutical company, today presented new clinical data on APX005M at the American Association for Cancer Research (AACR) Annual Meeting, taking place March 29 - April 3, 2019 in Atlanta, GA.

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced new data from two programs targeting a novel tumor specific embryonic antigen, human aspartate β-hydroxylase (ASPH), including preclinical data on SNS-723, a first-in-class CAR-T cell therapy demonstrating effective killing of tumor cells by a series of ASPH-specific CAR-Ts as well as additional data from its Phase 1 study on the long-term effects of SNS-301

The US Food and Drug Administration (FDA) has approved Fera’s New Drug Application (NDA) for Avaclyr™ (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis.

Florida Blue, the state’s leading health insurer, announced a partnership with Professor George Loewenstein of Carnegie Mellon University to develop consumer behavior analytics and testing strategies to help the company better engage with consumers so they can make more informed decisions that will lead to improved health outcomes.

Last week’s ruling by a U.S. District Court in Washington D.C. has, among other issues, endangered the operation of regionally defined association health plans (AHPs) under the Department of Labor’s June 2018 regulations.

CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the fourth quarter and year ended December 31, 2018 and provided an update on the Company’s business developments.

Kit CheckTM, the leader in automated medication management solutions for hospitals, today announced that its Bluesight for Controlled Substances diversion prevention and controlled substance management solution has closed over one million cases*.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, presented preclinical data on the therapeutic potential of an immunomodulatory CCL22-based vaccine

Young Living looks back at two-and-a-half decades of major milestones and skyrocketing success